265 related articles for article (PubMed ID: 16269995)
1. [The new antithrombotic agents].
Meyer Samama M
Presse Med; 2005 Oct; 34(18):1309-14. PubMed ID: 16269995
[TBL] [Abstract][Full Text] [Related]
2. [New anticoagulants -- their clinical significance].
Haas S
Ther Umsch; 2003 Jan; 60(1):19-23. PubMed ID: 12638473
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
5. [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Drouet L
Bull Acad Natl Med; 2003; 187(1):85-96; discussion 96-7. PubMed ID: 14556456
[TBL] [Abstract][Full Text] [Related]
6. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study).
Hong TT; Huang J; Driscoll E; Lucchesi BR
J Cardiovasc Pharmacol; 2005 Oct; 46(4):526-33. PubMed ID: 16160608
[TBL] [Abstract][Full Text] [Related]
7. New anticoagulants in ischemic heart disease.
Verheugt FW
Presse Med; 2005 Oct; 34(18):1325-9. PubMed ID: 16269997
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
9. [Preventing cerebrovascular accidents during atrial fibrillation].
Ederhy S; Meuleman C; Hammoudi N; Janower S; Boccara F; Cohen A
Presse Med; 2005 Oct; 34(18):1315-24. PubMed ID: 16269996
[TBL] [Abstract][Full Text] [Related]
10. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
11. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
12. [Advances in adjunctive pharmacological therapy for percutaneous coronary interventions].
Benito B; Masotti M; Betriu A
Rev Esp Cardiol; 2005 Jun; 58(6):729-43. PubMed ID: 15970124
[TBL] [Abstract][Full Text] [Related]
13. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Carlsson S; Elg M; Mattsson C
Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
[TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
15. [Direct thrombin antagonists].
Lankes W; Fleischer K; Gulba DC
Herz; 2001 Apr; 26 Suppl 1():46-52. PubMed ID: 11349627
[TBL] [Abstract][Full Text] [Related]
16. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
17. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Niessner A; Niessner H; Huber K
Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625
[TBL] [Abstract][Full Text] [Related]
18. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
19. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
20. [Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Averkov OV; Slavina NN; Gratsianskiĭ NA
Kardiologiia; 2003; 43(10):50-9. PubMed ID: 14593356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
